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Abstract: Obsessive-compulsive disorder (OCD) is a debilitating neuropsychiatric condition estimated to afflict 1-3% of 
the world population. The estimated financial impact in the treatment and management of OCD is in the billions of dollars 
annually in the US alone. At present there is a marked lack of evidence on the specific causes of OCD. Current hypotheses 
largely focus on the serotonin (5-HT) system on the basis of the effectiveness of selective serotonin reuptake inhibitors 
(SSRIs) in alleviating symptoms of patients with OCD, yet a considerable fraction of patients are non-responsive or 
minimally responsive to these agents. Despite this fact, SSRIs have remained the primary pharmacological treatment ave-
nue for OCD. In recent years, multiple lines of evidence have implicated glutamatergic synaptic dysfunction within the 
cortico-striatal-thalamo-cortical (CSTC) brain circuit in the etiology of OCD and related disorders, thereby prompting in-
tensified effort in the development and evaluation of agents that modulate glutamatergic neurotransmission for the treat-
ment of OCD. With this in mind, here we review the following topics with respect to synaptic dysfunction and the neural 
circuitry underlying OCD: (1) evidence supporting the critical involvement of the CSTC circuit, (2) genetic studies sup-
porting the involvement of glutamatergic dysfunction, (3) insights from genetic animal models of OCD, and (4) prelimi-
nary findings with glutamatergic neurotransmission-modulating agents in the treatment of OCD. Given the putative 
mechanistic overlap between OCD and the broader OC-spectrum of disorders, unraveling the synaptic basis of OCD has 
potential to translate into more effective treatments for an array of poorly understood human disorders. 
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subcortical, Synapse, Neurotransmission, Genetics, SAPAP3, Riluzole, Tourette’s syndrome, Trichotillomania, Neuropsy-
chiatric disorder, SSRI, N-acetylcysteine, Memantine, Orbitofrontal cortex, SLC1A1, GRIN2B, NMDA receptor, D-
cycloserine, Corticostriatal, Cortico-striatal. 
WHAT IS OCD? 
OCD Symptoms, Worldwide Prevalence, and Economic 
Impact 
  Obsessive-compulsive disorder is a debilitating neuro-
psychiatric condition characterized by persistent intrusive 
thoughts (obsessions) and the expression of ritualistic repeti-
tive behaviors (compulsions) which are generally enacted in 
an effort to somehow alleviate intense anxiety caused by 
specific obsessions. The majority of OCD sufferers are 
aware or become aware that their obsessions are irrational 
and their repetitive actions excessive, which only further 
exacerbates feelings of distress and anxiety due to an inabil-
ity to prevent such symptoms. As a significant proportion of 
time each day (>1 hour by definition) is generally absorbed 
by obsessions and compulsions, these symptoms can render 
sufferers incapacitated in their daily functioning [1, 2]. 
Commonly reported obsessions and compulsions are shown 
in Table 1. Although OCD can develop at any age, it most 
often develops in late adolescence to young adulthood. Left 
untreated, symptoms can persist throughout the lifetime, 
although the specificity and severity of symptoms may 
change with time.  
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Table 1.  Common Symptoms in OCD [1, 2] 
Obsessions 
excessive doubt about task completion 
fear of contamination or un-cleanliness 
need for symmetry or exactness 
fear of causing harm to others 
excessive concern over right and wrong 
intrusive inappropriate sexual thoughts 
Compulsions 
checking 
washing/cleaning 
counting 
ordering/arranging 
repeating 
hoarding 
praying 
 
  OCD is estimated to afflict roughly 1-3% of the world 
population [3-5] thus making it one of the most prevalent 
psychiatric disorders in our society. At last glance, the esti-Synaptic Dysfunction and OCD  Current Chemical Genomics, 2008, Volume 2    63 
mated financial impact in the treatment and management of 
OCD is several billions of dollars annually in the United 
States alone [6], and this cost is expected to rise with im-
provements in diagnosis, reporting, and availability of effec-
tive treatments.  
  Although the exact causes of OCD are unknown, many 
lines of evidence suggest that OCD has a genetic basis. Spe-
cifically, the concordance rate for OCD is greater among 
pairs of monozygotic twins (80-87%) than among pairs of 
dizygotic twins (47-50%, [7, 8]). Family studies of OCD also 
indicate that the risk to first degree relatives is 3-12 times 
greater than that for the general population [9]. Despite in-
tensive efforts, no common alleles have been directly linked 
to the pathogenesis of OCD, which is likely to reflect a com-
plex model of genetic susceptibility. 
The OC-Spectrum of Disorders 
  Based on commonalities in symptoms, comorbidity, neu-
rocircuitry, and response to drug treatments, OCD has been 
suggested to share etiology with a growing list of other neu-
ropsychiatric disorders. These include Body dysmorphic 
disorder (BDD), Tourette syndrome (TS), trichotillomania 
(TTM; compulsive hair pulling), compulsive skin-picking 
(CSP; also called dermatillomania) [10, 11]. Several other 
disorders have been suggested for inclusion (e.g. additional 
impulse control disorders and various eating disorders) al-
though no consensus has emerged as to the appropriate 
boundary of the OC spectrum—which is likely attributed to 
a poor understanding of many of these human disorders. 
Taken together, OC-spectrum disorders may conceivably 
affect as much as 10% of the general population [12]. 
CURRENT TREATMENTS FOR OCD 
  Despite a lack of understanding about the precise neuro-
biological mechanisms underlying OCD, treatments have 
been developed that are at least partially effective in alleviat-
ing symptoms. These treatments can be subdivided into ei-
ther pharmacological or behavioral therapies. 
Pharmacological Therapies 
  The current first-line drugs in the treatment of OCD are 
selective serotonin reuptake inhibitors (SSRIs). The SSRIs 
fluoxetine, fluvoxamine, sertraline, and paroxetine have been 
approved by the Food and Drug Administration (FDA) for 
the treatment of OCD, although paroxetine is not approved 
for use in pediatric cases. SSRIs act by blocking the presyn-
aptic serotonin transporter (5-HTT) that normally mediates 
the reuptake of synaptically released serotonin. All of the 
currently available SSRIs that have been investigated seem 
to exhibit similar efficacy in treating OCD symptoms. On 
average, SSRI responders see a modest but significant reduc-
tion of symptoms, whereas 40-60% of patients are unrespon-
sive to SSRI monotherapy [13, 14].  
  Notably, higher doses of SSRIs over longer periods of 
time (2-3 months) are necessary to achieve optimal anti-
obsessional benefits in comparison to their implementation 
in the treatment of major depression [14]. This delay in 
therapeutic benefit in the treatment of OCD is suggested to 
reflect the time course of serotonin receptor desensitization 
resulting from chronically elevated synaptic serotonin levels 
[15]. Long-term modifications at serotonin receptors are also 
indicated by the fact that acute interventions known to de-
crease serotonin transmission fail to disrupt the ongoing 
benefits of SSRI treatment in OCD patients [16]. 
  The tricyclic antidepressant clomipramine is often still 
considered a first-line drug in treating OCD symptoms, and 
there is some evidence to suggest superior efficacy relative 
to SSRIs; however, clomipramine is less well tolerated than 
the SSRIs and causes a broad range of side effects—likely 
due to anticholinergic effects [17]. Thus, clomipramine may 
be best utilized for patients that are refractory to SSRI treat-
ment.  
  Augmenting agents are employed when there is a partial 
response to SSRI monotherapy. Since this is the most likely 
outcome for the majority of cases, the use of augmenting 
agents is common, and this strategy is generally favored over 
switching to a different SSRI monotherapy since a partial 
response has been established. Examples of augmenting 
agents that are commonly employed include the antipsychot-
ics risperidone and haloperidol. A detailed guideline (algo-
rithm) for OCD pharmacotherapy can be found elsewhere 
[18]. 
Behavioral Therapies 
  A specific form of cognitive-behavioral therapy called 
exposure and response prevention (ERP) is an established 
and effective treatment for some OCD symptoms [19, 20]. 
ERP involves having the OCD patient repeatedly expose 
themselves to anxiety-inducing stimuli linked to frequent 
obsessions (e.g. contact with contaminated objects), fol-
lowed by a prevention of the rituals that typically ensue (e.g. 
hand washing). In this way the patient undergoes habituation 
to the aversive stimuli with repeated exposures. The re-
sponse prevention aspect is critical in allowing the patient to 
learn that the decreasing anxiety experienced with repeated 
exposure is not linked to the completion of compulsion-
induced rituals [21]. ERP has been shown to be equally or 
perhaps more effective in treating OCD symptoms than 
pharmacological treatments alone [22, 23], and the rate of 
relapse following cessation of treatment is significantly 
lower for ERP compared to pharmacological treatments 
alone [24]. Thus, cognitive-behavioral therapy may be im-
plemented as a first-line treatment and is a particularly valu-
able treatment option for SSRI refractory patients and pa-
tients that refuse pharmacological treatment altogether. Other 
structured psychotherapies such as cognitive therapy without 
ERP are also a valuable treatment option, particularly in 
cases where specific OCD symptoms are not amenable to 
ERP therapy [25]. 
Combined Therapy 
  There is some evidence that combined pharmacological 
and behavioral treatments (SSRIs or clomipramine combined 
with cognitive-behavioral therapy) are more effective than 
SSRI or clomipramine monotherapy, although it is unclear at 
this time if combined regimes offer significant benefits over 
cognitive-behavioral therapy alone [22, 26]. Even the most 
rigorous treatment regimes available today offer incomplete 
reprieve for most. Advances in our understanding of the ba-
sic neurobiological mechanisms underlying OCD are neces-
sary to guide the development of improved treatment op-
tions. 64    Current Chemical Genomics, 2008, Volume 2  Ting and Feng 
EVIDENCE SUPPORTING THE CORTICO-
STRIATAL-THALAMO-CORTICAL CIRCUIT AS A 
PRIMARY SITE OF SYNAPTIC DYSFUNCTION IN 
OCD 
Anatomy and Function of the CSTC Circuit 
  In 1983, Penney and Young displayed remarkable insight 
in their description of the CSTC circuit and the role of this 
circuit in the control of normal movement, as well as in the 
context of movement disorders [27]. In particular, their 
model mechanistically explains the central role of the basal 
ganglia within this CSTC circuit for the selection of which 
behaviors will be carried out and the exclusion of unwanted 
behaviors.  
  Subsequent work has firmly established that the CSTC 
circuit is composed of numerous parallel open loops that 
functionally link the frontocortical and subcortical areas [28-
30]. It is believed that different sets of frontocortical-
subcortical loops participate in specialized motor and cogni-
tive functions as determined by the specific frontocortical 
area involved [31]. Cortical neurons send dense projections 
into the striatum which form glutamatergic cortico-striatal 
synapses onto medium spiny neurons (MSNs). In turn, 
GABAergic MSNs connect to the major output structures of 
the basal ganglia, the globus pallidus pars internalis (GPi) 
and substantia nigra pars reticulata (SNr), by way of two 
anatomically distinct pathways that are thought to have op-
posing roles. Dopamine receptor type 1 (D1R) expressing 
MSNs in the striatum compose the “direct pathway” (striato-
nigral), whereas dopamine receptor type 2 (D2R) expressing 
MSNs in the striatum compose the “indirect pathway” (stia-
topallidal) [32]. The direct pathway axons terminate in 
GPi/SNr, whereas the indirect pathway involves a more 
complex relay successively involving the globus pallidus 
pars externalis (GPe) and subthalamic nucleus (STN). In a 
simplified model, the output structures of the basal ganglia 
provide inhibitory tone to the thalamus, and this tone is 
modulated by the balance of activity through the direct and 
indirect pathways (the so-called “accelerator-brake” model) 
[33]. In this way, a shift of balance favoring activity in the 
direct pathway will “disinhibit” the thalamus and thereby 
promote the selection of behavioral sequences. Conversely, a 
shift of balance favoring activity in the indirect pathway has 
a net effect of reinforcing or strengthening the inhibitory 
tone to the thalamus and thereby inhibits the selection of 
behavioral sequences. The thalamus sends excitatory inputs 
back to the cortex, thereby completing the CSTC loop (Fig. 
1). Although highly simplified, this model of the CSTC cir-
cuit provides a useful framework for understanding CSTC 
circuit dysfunction in OCD. 
Imaging Studies Implicating CSTC Circuit Dysfunction 
in OCD 
  The use of non-invasive neuroimaging methods to probe 
for abnormalities in the brains of human patients with OCD 
has led to extensively replicated findings supporting the in-
volvement of the CSTC circuit in OCD (thoroughly re-
viewed in [34]). Numerous early studies using Positron 
Emission Tomography (PET) or single photon emission CT 
(SPECT) have consistently reported increased glucose me-
tabolism and blood flow (pretreatment baseline or during 
symptom provocation) in one or more of the following re-
gions: orbitofrontal cortex, anterior cingulate cortex, caudate, 
and thalamus [35-40]. These regions are the principle com-
ponents of the CSTC circuit (Fig. 1). As a complement to 
this approach, additional PET and SPECT studies were per-
formed on OCD patients before and after treatment. These 
studies reported decreased glucose metabolism and blood 
flow within the same CSTC regions, mainly using SSRI or 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The Cortico-striatal-thalamo-cortical loop is a major site of synaptic dysfunction in OCD. (A) Diagram of a mouse brain (sag-
ittal view) illustrating the major brain regions that compose the CSTC loop. Hyperactivity in specific cortical-subcortical loops involving 
areas such as the orbitofrontal cortex is hypothesized to lead to the expression of OCD symptoms. (B) Simplified circuit diagram of the 
CSTC loop in mammals. MSN, medium spiny neuron; GPe, globus pallidus pars externalis; GPi, globus pallidus pars internalis; SNc, sub-
stantia nigra pars compacta; SNr, substantia nigra pars reticulate; STN, subthalamic nucleus; D1R, D1-type dopamine receptor; D2R, D2-
type dopamine receptor. Panel (A) adapted from [32]. 
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clomipramine treatment [41-45], but also with behavioral 
therapy [43, 46] and neurosurgical lesion [47]. Qualitatively 
similar results in OCD patients (i.e. alterations within the 
CSTC circuit) have been reported for both the pre- and post 
treatment assessments using magnetic resonance spectros-
copy (MRS) to measure regional concentrations of amino 
acid neurotransmitters in general [48-50].  The observed 
changes with MRS are often cited as reflecting alterations in 
glutamate, although this is not the only possibility (see [51] 
for further discussion on the limitations of MRS in this con-
text).  
  According to a prominent model put forth by Baxter et 
al. [34, 52] which integrates findings from key imaging stud-
ies and extends the proposals of others [53, 54], OCD symp-
toms may be caused by hyperactivity in the orbitofrontal-
subcortical loops as a consequence of imbalance in the basal 
ganglia pathways. Persistent activation of the direct pathway 
has been suggested, which is proposed to lead to inappropri-
ate, potentially repetitive release of cognitive and motor se-
quences. The release of such cognitive and motor sequences 
or “action chunks” become pathological because they are no 
longer under the control of intent despite being consciously 
performed [55]. See also [56] for a detailed review regarding 
the orbitofrontal-subcortical model of OCD in the context of 
neuroimaging studies. 
Last-Resort Treatment Options for OCD Disrupt CSTC 
Circuits 
  This hypothesis of frontocortical hyperactivity in OCD 
also fits well with the reported beneficial effects of certain 
invasive neurosurgical interventions for treatment refractory 
OCD. Anterior cingulotomy, anterior capsulotomy, and sub-
caudate tractotomy and capsulotomy are all designed to dis-
rupt connections between frontocortical and subcortical areas 
within the CSTC circuit, and a significant percentage of pa-
tients improve following these surgeries [57, 58]. High-
frequency deep brain stimulation (DBS) has also been ex-
plored for treatment resistant OCD as an alternative to per-
manent ablation/lesion options. In cases where DBS was 
successfully employed, the lessening of OCD symptoms was 
accompanied by a reduction in the activity of orbitofrontal 
cortical regions as measured by PET [59, 60]—thus mirror-
ing the earlier findings using more conventional treatment 
options. The site of DBS in these studies was the anterior 
internal capsule, which may lead to disruption of the connec-
tions between thalamus and orbitofrontal cortex [60]. Addi-
tional studies have shown effectiveness of DBS in the nu-
cleus accumbens (NAc) region in OCD [61, 62], and an in-
vestigation into the detailed mechanism of NAc DBS in rats 
found that activity in orbitofrontal cortex was reduced 
through a complex form of recurrent inhibition involving 
antidromic activation of cortico-striatal axon collaterals [63] 
OCD Precipitated by Basal Ganglia Disruptions 
  Symptoms of OCD have been reported in several cases 
involving brain lesions. Laplane [64] reported OCD-like 
symptoms in several patients that had bilateral lesions of the 
basal ganglia. Another study reported 5 cases of OCD occur-
ring late in life, all involving lesions of the basal ganglia 
[65]. Thus, these lesion studies are consistent with the pro-
posed critical involvement of the CSTC circuit, although 
such lesions must impact the CSTC circuit in a fundamen-
tally different way than the aforementioned neurosurgical 
lesions shown to alleviate rather than exacerbate OCD symp-
toms. 
  In addition to OCD symptoms brought on by brain le-
sions, acquired forms of OCD can also result from infection. 
Rheumatic fever is triggered by group A beta-hemolytic 
streptococcal infections (GAS) in children. A fraction of 
children with rheumatic fever develop a movement disorder 
known as Sydenham’s chorea (SC). Available evidence sug-
gests that the pathophysiology of SC involves an autoim-
mune mechanism whereby antibodies triggered by the GAS 
infection cross-react with neurons in the basal ganglia caus-
ing inflammation and compromised basal ganglia function 
[66]. It has long been recognized that OCD symptoms fre-
quently accompany SC, and several clinical studies have 
substantiated this association [67-69]. Cases of OCD and TS 
are also observed in children following GAS infection, but in 
the absence of clinically defined SC, and this group has been 
referred to as pediatric autoimmune neuropsychiatric disor-
ders associated with streptococcal infections (PANDAS) 
[70].  
Involvement of Other Brain Circuits in OCD 
  Defects in other brain regions are also likely to play a 
role in OCD and should be mentioned. For example, there is 
evidence for involvement of the limbic system with respect 
to the anxiety component of OCD. Altered amygdala volume 
and dysfunctional amygdala activation have been reported in 
OCD patients [71-73], and the amygdala has a well estab-
lished role in the expression of fear and anxiety [74, 75]. In 
addition, although the CSTC circuit is proposed to mediate 
some aspects of disgust relevant to fear of contamination in 
OCD, there is further evidence that discrete circuits in the 
insular cortex are a primary loci of disgust (reviewed in 
[76]). 
GENETIC STUDIES SUPPORTING GLUTAMATER-
GIC DYSFUNCTION IN OCD 
  Although numerous lines of evidence have implicated 
dysfunction of the CSTC circuit in OCD, the precise nature 
of the defect(s)—including information regarding which 
neurotransmitter systems are primarily affected—has not 
been detailed. No causal relationship has been established in 
the etiology of OCD. Most hypotheses on the causes of OCD 
have focused on the serotonin system on the basis of positive 
benefits of SSRIs in treating OCD symptoms [77]. However, 
the limited effectiveness of SSRIs suggests the critical in-
volvement of other neurotransmitter systems. 
  Evidence for the involvement of the glutamatergic sys-
tem in OCD is steadily mounting. Frontocortical hyper-
glutamatergic function has been proposed to account for the 
CSTC abnormalities observed in imaging studies of OCD 
[34], and in support of this model, a recent small study dem-
onstrated elevated CSF glutamate levels in adult OCD pa-
tients compared to normal controls [78]. The model also im-
plies that genes involved in glutamatergic neurotransmission 
are good candidates for genetic association studies in 
OCD—and indeed, several studies (as detailed below) have 
reported associations in just the last few years. It is important 
to keep in mind that numerous genetic studies support the 
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transmitter systems in OCD (though many of the findings are 
controversial), and an extensive review of these studies can 
be found elsewhere [77].  
GRIN2B 
  In 2004, Arnold et al. [79] provided the first report of a 
positive association between a glutamatergic system gene 
and OCD. This study demonstrated preliminary association 
of one variant in the GRIN2B gene encoding the N-methyl-
D-aspartate (NMDA) receptor subunit 2B. This gene is 
highly expressed in the CSTC circuit, and NMDA-type glu-
tamate receptors have a well established role in basic synap-
tic transmission, synaptic plasticity mechanisms underlying 
learning and memory, and neuropsychiatric disorders (see 
[80, 81] for detailed reviews). Of particular interest, the 
subunit composition of NMDA receptors is dynamically 
regulated during development and is important in determin-
ing the functional properties of the receptor [81]. Interest-
ingly, Arnold et al. hypothesized the involvement of NMDA 
receptor gene variations in OCD based on neuroimaging 
findings of deficient striatal activation during learning tasks 
in OCD patients [82], thereby demonstrating the potential 
utility of integrating neuroimaging and genetic studies. The 
findings of this study have yet to be replicated and thus 
should be regarded as preliminary. 
SLC1A1/EAAC1 
  In 2006, Arnold et al. [83] and Dickel et al. [84] simulta-
neously published independent studies demonstrating that 
variants in the solute carrier family 1, member 1 gene 
SLC1A1 are associated with OCD. SLC1A1 encodes the neu-
ronal glutamate transporter excitatory amino acid carrier 1 
(EAAC1). These studies were in follow-up to the first ge-
nome-wide linkage study for OCD that provided evidence 
suggestive of an OCD susceptibility gene in the chromoso-
mal region 9p24 [85], a result that was later validated in a 
focused replication study [86]. The region 9p24 contains 
numerous predicted and known genes; however, of the 
known genes in this region at the time, SLC1A1 was the only 
one with expression in the brain according to Arnold et al. 
[83]. Of particular interest, SLC1A1 is highly expressed in 
brain regions comprising CSTC circuits [87, 88]. A third 
independent investigation [89] also confirmed an association 
between OCD and SLC1A1 for both single marker and 
haplotype single nucleotide polymorphisms (SNPs) in the 3’ 
region of the gene, consistent with the earlier studies [83, 
84]. Although the findings of the three studies are not identi-
cal, it has been suggested that the associated SNPs and 
haplotypes identified thus far may be in linkage disequilib-
rium with a yet unsampled, potentially causal SNP in the 3’ 
region of SLC1A1 [89]. In all three studies, subgroup analy-
sis by gender revealed specific associations of this gene with 
OCD for males but not females. Thus, considerable consis-
tency has been established in the reported associations be-
tween SLC1A1 and OCD.  
  The work on SLC1A1 also yields important lessons for 
evaluating the results of other candidate gene studies. An 
initial attempt failed to support association of SLC1A1 with 
OCD (but did confirm SLC1A1 as a positional candidate by 
mapping this gene within the 9p24 region) [90]. This earlier 
negative result has been attributed to small sample size and 
incomplete coverage of the SLC1A1 gene region, and indeed 
association of SLC1A1 with OCD became apparent in a more 
thorough study by the same group in 2006 [84]. In light of 
this, a negative result in attempted gene association studies 
only provides strong evidence for the lack of an association 
when the sample size is appropriately large and the selected 
markers provide excellent coverage of the gene region under 
investigation.  
GRIK2 & GRIK3 
 Delorme  et al. [91] investigated potential association 
between OCD and the ionotropic kainate receptors GRIK2 
and GRIK3. This study found no evidence for association for 
three SNPs in GRIK2 and one SNP in GRIK3, however, a 
separate transmission disequilibrium test revealed a signifi-
cant under-transmission of the I867 allele of SNP rs2238076 
in OCD. Notably, there is increasing evidence for GRIK2 
variations associated with autism [92-94], a disorder with 
manifestations that include compulsive-repetitive behavior 
similar to OCD. 
SAPAP3 
  SAP90/PSD95-associated protein 3 (SAPAP3) is a post-
synaptic scaffolding protein at excitatory synapses that is 
highly expressed in the striatum [95]. Recent evidence from 
the SAPAP3 null mouse demonstrates the importance of this 
protein in regulating cortico-striatal synaptic function [96]. 
Thus, SAPAP3 is an important component within the CSTC 
circuit. This is further established by the finding that the SA-
PAP3  null mice exhibit OCD-like behaviors (see also the 
following section on genetic mouse models for further de-
tails) [96]. These findings prompted two recent genetic stud-
ies of SAPAP3 and OCD.  
 Züchner  et al. [97] performed SAPAP3  gene re-
sequencing analysis in OCD and TTM case samples. This 
study identified seven rare non-synonymous heterozygous 
SAPAP3 variants. The combined load of these rare SAPAP3 
mutations was 4.2% of the OCD/TTM case samples com-
pared to only 1.1% in control samples, providing tentative 
support for a role of SAPAP3 in OCD and TTM. The major-
ity of the variants represented missense mutations, some of 
which are predicted to be possibly detrimental to protein 
function based on computer algorithms. These findings await 
further validation, including analysis of the functional rele-
vance of these rare SAPAP3 mutations. 
  A relatively large family-based gene association study of 
SAPAP3  in OCD and grooming disorders (GD) has been 
conducted by Bienvenu et al. [98]. This study explored 6 
SNPs spanning region 1p35 of the SAPAP3 gene. The pre-
liminary evidence suggests that multiple variations in the 
SAPAP3 gene are associated with GD. No clear association 
between SAPAP3 variants and OCD was reported, although 
it is noteworthy that GDs without OCD were uncommon in 
this study. With this in mind the authors suggest the possibil-
ity that SAPAP3 variants may be involved in a subtype of 
OCD involving pathological grooming behaviors.  
Summary of Genetic Studies in OCD  
  Studies reporting genetic linkage or association which are  
subsequently replicated merit continued focus. As detailed   
above, the most reliable evidence for gene association in   
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which together with recent reports of association for other  
genes directly involved in glutamatergic signaling at syn- 
apses has provoked a shift in attention to glutamatergic neu- 
rotransmission as a target for OCD pharmacotherapy. It is  
critical to point out that evidence for genetic association does  
not imply causality, and that OCD is a complex disorder that  
is likely to have a polygenic basis. Furthermore, genetic as- 
sociation studies leave open the mechanism by which spe- 
cific genetic variations may disrupt CSTC circuit function in  
OCD. Progress in this area will most likely be facilitated by  
detailed investigations in animal models of OCD. 
GENETIC ANIMAL MODELS OF OCD 
  Animal models serve as invaluable platforms for the de- 
velopment, screening, and refinement of pharmacological   
agents for the treatment of human disorders. They are also  
amenable to invasive research techniques not suitable for   
studies involving human patients. At present there are sev- 
eral behavioral, pharmacological, and genetic animal models  
of OCD that vary greatly in the extent to which they model  
the human condition (reviewed extensively in [99, 100]).   
Arguably, genetic animal models hold the most promise for  
rapid progress in our understanding of the basic neurobiol- 
ogy of OCD. This is true because the specific genetic disrup- 
tion is often known, and in many cases there exists prior   
knowledge (such as mRNA or protein expression pattern)   
such that the investigators possess a priori mechanistic in-
sight that can help explain many observed phenotypes. With  
this in mind, we selectively overview the existing genetic   
animal models (summarized in Table 2), including two very  
recently characterized genetic mouse models of OCD. The  
validity of each model is discussed along with how the   
model has (or has not) contributed to our understanding of  
synaptic dysfunction in OCD. 
D1CT-7 Transgenic Mice 
  The first genetic mouse model of OCD was reported in  
1999 by Campbell et al. [101]. Transgenic mice were gener- 
ated in which the expression of an intracellular form of the  
neuropotentiating cholera toxin (CT) is controlled by the D1- 
type dopamine receptor promoter elements (termed D1CT   
mice). D1CT mouse lines have chronically elevated neuronal  
activity restricted to D1 positive subsets of neurons in the  
brain.  
  In one particular line of D1CT mice (D1CT-7) transgene 
expression was found to be predominantly restricted to D1 
positive neurons within the intercalated nucleus of the 
amygdala and within cortical areas that project to orbitofron-
tal cortex and striatum. Chronic potentiation of these D1 
positive neuronal subsets was suggested to stimulate cortico-
striatal glutamatergic transmission, although this has not 
been directly validated. D1CT-7 mice exhibited repetitive 
biting of littermates that was unrelated to aggression, repeti-
tive leaping, and extended bouts of repetition during normal 
behaviors [101]. These mice also exhibited increased anxiety 
levels according to several behavioral measures [102]. Thus, 
the D1CT mice present behavioral features with similarity to 
OCD. The contention that hyper-glutamatergic transmission 
in cortical regions projecting to striatum drives the observed 
OCD-like behaviors provides a potential overlap with the 
putative neural underpinnings of human OCD. Direct meas-
urements of cortico-striatal transmission supporting this con-
tention would solidify the status of D1CT mice as a useful 
tool in OCD research. 
  Interestingly, a subsequent study provided evidence for 
TS-like behaviors in D1CT-7 mice, arguing that these mice 
may more accurately serve as a model for OCD with comor-
bid TS [103]. TS-like behaviors were ameliorated by small 
doses of the noradrenergic agent clonidine, which can have 
beneficial effects in TS patients [104]. Clonidine alone is not 
considered an effective treatment for OCD symptoms, and 
importantly, the response to SSRIs has not been evaluated 
thus far in D1CT mice. 
Hoxb8 Mutant Mice  
  Hoxb8 is a member of the large Hox (homeobox-
containing) family of mammalian transcription factors best 
known for their role in early development [105]. Intrigu-
ingly, Hoxb8 is broadly expressed in adult brain, with ex-
pression in the olfactory bulb, basal ganglia, hippocampus, 
cortex, cerebellum, and brain stem [106]. To address the role 
of Hoxb8 in the adult brain, Greer and Capecchi [106] cre-
ated mice homozygous for a loss-of-function allele of 
Hoxb8. These mice showed excessive grooming that led to 
Table 2.  Evaluation of Genetic Animal Models of OCD 
Genetic Model  Face Validity*  CSTC Circuit Expression^  CSTC Synaptic Dysfunction  Response to SSRIs 
D1CT Tg  +++  ++  ++  nd 
Hoxb8 mutant  +++ +++  nd  nd 
5-HT2C null  +  +  nd  nd 
ArKO ++  ?  nd  nd 
DAT KD  +  +++  +++  nd 
SAPAP3 null  +++ +++  +++ ++ 
D1CT Tg, transgenic mouse line in which neuropotentiating cholera toxin is expressed under the D1-type dopamine receptor promoter elements; Hoxb8 mutant, homozygous loss-of-
function for mammalian transcription factor Hoxb8; 5-HT2C null, null mutant mouse for the 5-HT2C subtype of the serotonin receptor; ArKO (for aromatase knock-out), estrogen 
deficient mouse line resulting from elimination of aromatase expression; DAT KD, dopamine transporter knock-down mice with DAT levels reduced to 10% of wild-type values; 
SAPAP3 null, null mutant mouse for the postsynaptic scaffolding protein SAPAP3. 
*Note that face validity incorporates both behavioral similarity AND specificity. 
^CSTC circuit expression refers to the extent to which the gene or Tg is expressed in these brain regions. 
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hair removal and skin lesions both of self and wild-type cage 
mates. The excessive grooming was manifest in the absence 
of any skin abnormalities and developed with 100% pene-
trance. The authors proposed that the behaviors of Hoxb8 
mutant mice mirror those observed for OCD and TTM, an 
OC-spectrum disorder.  
  The extensive expression of Hoxb8 in virtually all re-
gions of the CSTC circuit that is disrupted in OCD indicates 
strong potential for the involvement of Hoxb8 gene disrup-
tion in forms of human OCD and/or TTM. Such broad ex-
pression of Hoxb8 throughout the adult brain may also ac-
count for possible atypical features that could be unrelated to 
OCD, such as the observed excessive grooming of wild-type 
cage mates, which in principle could represent abnormal 
aggression. The Hoxb8 mutant mice have not been tested for 
response to SSRIs, and the neural basis for their OCD-like 
behaviors remains entirely unexplored. 
5-HT2C Null Mice 
 The  5-HT2C subtype of the serotonin receptor family is a 
G-protein coupled receptor (GPCR) that is broadly expressed 
in the brain and is proposed to mediate many of the central 
nervous system actions of serotonin, including those under-
lying the therapeutic benefit of SSRI treatment in OCD [15]. 
The initial characterization of mice lacking the 5-HT2C re-
ceptor indicated that these mice were hyperphagic, leading to 
obesity, and were prone to spontaneous death from severe 
seizures [107]. In a much later study, Chou-Green et al. 
[108] characterized compulsive aspects of 5-HT2C null 
mouse behavior that were more representative of OCD-like 
behaviors. These mice exhibit increased chewing of non-
nutritive clay, ‘neat’ patterns of chewing on plastic screens, 
and perseverative head dipping behaviors. The chewing ab-
normalities have been likened to the human OCD symptom 
of checking, ordering, smoothing, or washing, whereas per-
severative head dipping has been likened to the human 
symptom of compulsive checking. Despite these similarities 
and the known involvement of serotonin signaling in the 
CSTC circuit, the presence of such dominant atypical fea-
tures (namely obesity and seizure) in the 5-HT2C null mice 
poses a formidable challenge in applying this model in a 
context that will be informative specifically to OCD. 
DAT Knock-Down Mice 
  The dopamine transporter (DAT) gene encodes the mem-
brane transporter protein that is responsible for the clearance 
and recycling of synaptically released dopamine. Based on 
evidence implicating abnormal dopaminergic neurotransmis-
sion and involvement of the DAT protein in schizophrenia 
and attention deficit hyperactivity disorder (ADHD), Zhuang 
et al. [109] set out to create a model of these conditions by 
knock-down (KD) of DAT levels to only 10% of wild-type 
values. The resulting hyperdopaminergic mutant mice did 
not exhibit confounding growth defects as did the pre-
existing DAT null mice, but did recapitulate hyperactivity in 
response to novelty similar to what was previously observed 
in DAT null mice. Amphetamine administration resulted in 
reduced hyperactivity, consistent with the beneficial effects 
of amphetamine and methylphenidate in the treatment of 
ADHD, and lending support for the DAT KD mouse as a 
model for ADHD. 
  A later study employing hyperdopaminergic DAT KD 
mice characterized overly-rigid grooming behavior that was 
referred to as sequential super-stereotypy [110]. Because 
overly rigid sequential patterns of action, language, and 
thought are characteristic of the symptoms of OCD and TS, 
by analogy, the DAT KD mice can be said to model these 
conditions in a very straightforward sense. However, despite 
the extensive characterization of sequential super-stereotypy 
in DAT KD mice, additional studies with DAT KD mice 
have provided evidence to suggest that behavioral abnor-
malities in these mice model aspects of mania, bipolar disor-
der [111], and drug addiction [112] in addition to ADHD, 
OCD, and TS. Thus, a consideration of the specificity of 
behavioral features (i.e. lack of atypical features) in addition 
to the similarity of symptoms with respect to OCD in hu-
mans is valuable in assessing face validity. This considera-
tion is particularly relevant in evaluating the 5-HT2C null and 
DAT KD mice as models for OCD.  
  The importance of the DAT protein in dopaminergic neu-
rotransmission in the basal ganglia suggests extensive in-
volvement of CSTC circuit abnormalities in sequential su-
per-stereotypy in the DAT KD mouse model. This has been 
directly demonstrated in recordings from brain slice of DAT 
KD mice [113]. DAT KO mice were found to have altered 
cortico-striatal excitatory transmission as well as diminished 
modulation of synaptic responses by cocaine and ampheta-
mine, which may result from reduced function of D2 recep-
tors in response to chronically elevated dopamine levels in 
the striatum [113]. The question still remains as to whether 
these synaptic abnormalities are germane to OCD-like be-
haviors versus one or more of the various other disorders the 
DAT KO mice are suggested to model. The effects of SSRI 
treatment on the reported synaptic alterations and the se-
quential super-stereotypy have not been investigated. 
ArKO Mice 
  The enzyme aromatase converts androgen to estrogen. 
Hill et al. [114] eliminated aromatase expression by targeted 
disruption of the Cyp19 gene, thereby producing estrogen 
deficient mice (designated ArKO mice). The absence of es-
trogen in adult male (but not female) mice led to compulsive 
behaviors including excessive grooming, barbering, and 
wheel running. ArKO male mice therefore exhibit behaviors 
that share similarities with symptoms of OCD patients.  
  The OCD-like behaviors of male ArKO mice are sug-
gested to be caused by dysregulation of estrogen-induced 
catechol-O-methyltransferase (COMT) expression in the 
hypothalamus. This disruption is likely to influence dopa-
mine signaling since COMT is a major enzyme regulating 
dopamine degradation [115]. In contrast, estrogen deficiency 
had no impact on COMT expression in the frontal cortex of 
male ArKO mice. This profile of brain region specific regu-
lation of COMT by estrogen in ArKO mice is not in accord 
with CSTC circuit dysfunction in OCD. Given that some 
evidence exists to support the involvement of the hypo-
thalamus in grooming and running wheel behaviors [116, 
117], it seems plausible that the compulsive behaviors exhib-
ited by male ArKO mice have an etiology that is distinct 
from human OCD involving CSTC circuit dysfunction. In 
light of the evidence that low COMT activity is a risk factor 
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given that only two brain regions were analyzed in the initial 
study, perhaps a more detailed evaluation of COMT expres-
sion in the brain is warranted in male ArKO mice. Such ex-
tension could clarify the neurocircuitry involved and thus 
resolve what appears to be a mechanistic disconnect. 
  Estrogen replacement therapy for three weeks attenuated 
OCD-like compulsive behaviors in male ArKO mice, indi-
cating that developmental defects resulting from the loss of 
estrogen are not likely to be involved in the observed pheno-
type. However, this finding does not rule out the involve-
ment of potentially confounding effects related to estrogen 
depletion in non-neuronal tissues. Overall, the relevance of 
this model to OCD is promising but at present is not well 
established. Future assessment of the potential benefits of 
SSRIs and further clarification of the neurocircuitry involved 
will be required to extend the validity of the ArKO mouse 
model of OCD beyond simply face validity. 
SAPAP3 Null Mouse Model of OCD 
  SAP90/PSD95-associated protein 3 (SAPAP3) belongs to 
a family of four homologous genes encoding SAPAP pro-
teins that are widely yet differentially expressed in the nerv-
ous system [95]. The SAPAP family of proteins is found at 
excitatory synapses and was originally identified as a family 
of proteins that interacts with postsynaptic density-95 (PSD-
95) and Shank family members [121-123]. By virtue of their 
interactions with each other and with various signaling 
molecules, these three groups of major scaffolding proteins 
at the postsynaptic density (PSD) of excitatory synapses are 
proposed to be central players in the dynamic regulation of 
glutamatergic synaptic signaling [124].  
  SAPAP3 is the only family member that is strongly ex-
pressed in the striatum [95], thus offering a unique opportu-
nity to explore the specific function of SAPAP3 at glutama-
tergic synapses in this brain region. Genetic deletion of the 
SAPAP3 gene in mice caused behavioral abnormalities con-
sisting of increased anxiety and compulsive self-grooming to 
the point of facial hair loss and skin lesions [96]. These fea-
tures share similarity with various aspects of symptoms ex-
hibited by human patients with OCD, as demonstrated for 
other genetic animal models of OCD. Consistent with the 
predicted function of the SAPAP3 protein, SAPAP3  null 
mice were also found to have defects in glutamatergic 
transmission at cortico-striatal synapses (a feature that is 
only known to be shared by the DAT KD mice thus far, but 
has been suggested as a central defect for D1CT mice), and 
remarkably, both synaptic and behavioral defects were res-
cued by virus-mediated reintroduction of SAPAP3 specifi-
cally into the striatum [96]. Further work is necessary to elu-
cidate the exact nature of the glutamatergic synaptic defects 
in these mice. 
  Given the high expression and postsynaptic localization 
of SAPAP3 at glutamatergic synapses in the striatum, these 
findings fit well within the existing framework of glutama-
tergic dysfunction in the CSTC circuit in OCD. Finally, the 
SAPAP3 null mouse model is the only genetic mouse model 
of OCD for which predictive validity has been established in 
that chronic administration of fluoxetine successfully allevi-
ated measures of anxiety and compulsive grooming. Thus, 
the  SAPAP3  null mouse model provides significant ad-
vancement over the existing genetic animal models of 
OCD—particularly from the perspective of CSTC circuit 
dysfunction. With this in mind, the SAPAP3  null mouse 
model should serve as a useful tool in the screening of novel 
drugs for the treatment of OCD.  
  As a final consideration regarding genetic animal models, 
it will also be critical to tests drugs that have been shown not 
to be effective in treating OCD, as suggested by Joel [99], as 
it is well established that SSRIs are only effective in about 
half of OCD patients. Furthermore, without establishing a 
drug response profile involving multiple drugs, caution is 
necessary when interpreting “negative results” of drug 
screening using animal models of OCD. Investigators using 
animal models in this manner—particularly in the testing of 
SSRIs—should also consider implementing criteria to distin-
guish treatment responders from non-responders, which may 
lead to a system for specifically exploring treatment resistant 
OCD in animal models. 
GLUTAMATERGIC NEUROTRANSMISSION-BASED 
PHARMACOTHERAPY FOR OCD AND OC-
SPECTRUM DISORDERS: IMPLICATIONS FOR 
NEW DRUG DEVELOPMENT 
  The recent findings concerning the neural basis of OCD 
arising from diverse studies validate an intensified focus on 
glutamatergic synaptic dysfunction within the CSTC circuit. 
Thus, it is not surprising that numerous glutamatergic neuro-
transmission-modulating agents are currently being tested in 
the treatment of OCD. Many of these drugs have previously 
been approved for treatment of other disorders, which should 
speed progress in the search for novel OCD treatments since 
information on tolerability and pharmacokinetics are ex-
pected to be readily be available. Table 3 summarizes candi-
date glutamatergic neurotransmission modulating agents for 
the treatment of OCD as discussed in detail below. 
Riluzole – a Glutamatergic Neurotransmission Modulat-
ing Agent  
  Riluzole is one such drug that has received considerable 
attention in the OCD field in recent years. This drug was 
previously approved by the FDA for the treatment of 
amyotrophic lateral sclerosis (ALS) and has a reasonably 
good record of safety in that context [125]. Riluzole is sus-
pected to reduce glutamate release in the brain via multiple 
presynaptic mechanisms [126, 127], although it may also act 
by stimulating glutamate uptake by astrocytes [128]. In the 
first open-label trial of riluzole augmentation for treatment 
resistant OCD by Coric et al. [129, 130], 7 out of 13 patients 
showed improvements on riluzole, with 5 qualifying as 
treatment responders by additional criteria. Members of this 
same research group have recently followed-up with another 
open-label trial of riluzole employing similar design and 
with an equal number of patients. Again, 7 out of 13 patients 
showed significant improvements during the course of 
treatment with riluzole [131]. An open-label trial of riluzole 
in children with treatment resistant OCD produced qualita-
tively similar results, with 4 out of 6 patients classified as 
riluzole treatment responders [132]. Interestingly, a recent 
case study reported that riluzole was effective in treating the 
combined symptoms of OCD and pathological/compulsive 
skin picking (CSP) [133], and another case study found simi-
lar benefits in a patient with TTM [134], suggesting that this 
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Table 3.  Summary of Candidate Glutamatergic Neurotransmission Modulating Agents for the Treatment of OCD 
Drug Name   FDA Approval   Mechanism(s) of Action   OCD Studies  Effectiveness 
riluzole  ALS   reduction of synaptic glutamate release 
via multiple presynaptic mechanisms; 
stimulation of glutamate uptake by 
astocytes 
Pittenger et al. 2008 [135] 
Coric et al. 2005 [130] 
Grant et al. 2007 [132] 
Coric et al. 2003 [129] 
Coric et al. 2007 [134] 
slightly more than half of 
the 32 total OCD patients 
treated open-label with 
riluzole have shown sig-
nificant improvements 
topiramate epilepsy  block of voltage-dependent Na
+ and 
K
+ channels; reduction of 
AMPA/kainate receptor channel con-
ductance; positive modulatory actions 
on GABAA receptors 
Van Ameringen et al. 2006 [137] 
Hollander & Dell'Osso, 2006 [138]  
*Ozkara et al. 2005 [140] 
12/17 cases showed im-
provements; topiramate 
induced OCD symptoms in 
one isolated case report 
lamotrigine  epilepsy, bipolar 
disorder 
inhibition of voltage-dependent Na
+ 
channels to reduce synaptic glutamate 
release from neurons 
Kumar & Khanna, 2000 [139]  
*Alkin et al. 2007 [141] 
*Kuloglu et al. 2008 [142] 
*Kemp et al. 2007 [143] 
1/8 OCD patients showed 
benefit; lamotrigine in-
duced OCD symptoms in 7 
cases from 3 other studies 
N-acetylcysteine  acetaminophen toxic-
ity 
stimulation of the glial cys-
tine/glutamate exchanger resulting in 
activation of mGluR2 receptors which 
dampens presynaptic glutamate release 
from neurons during bouts of exces-
sive neuronal activity  
Lafleur et al. 2006 [146]  a single case report indi-
cates potential benefit as 
augmenting agent 
LY354740  N/A  agonist of type II metabotropic gluta-
mate receptors; dampens presynaptic 
glutamate release from neurons during 
bouts of excessive neuronal activity 
No studies in OCD patients  N/A 
memantine  Alzheimer's disease   NMDA-type glutamate receptor open-
channel blocker (moderate antagonist 
relative to dizocilpine) 
Pasquini & Biondi, 2006 [150]  
Poyurovsky et al. 2005 [151] 
2/3 OCD patients treated 
with memantine showed 
improvements 
amantadine  influenza A virus 
infection, Parkinson's 
disease 
NMDA-type glutamate receptor open-
channel blocker (moderate antagonist 
relative to dizocilpine) 
No studies in OCD patients  N/A 
dizocilpine (MK-
801) 
N/A  NMDA-type glutamate receptor open-
channel blocker (high-affinity antago-
nist relative to memantine/amantadine) 
No studies in OCD patients  exacerbates OCD symp-
toms in the D1CT mouse 
model [154] 
D-cycloserine 
(DCS) 
antibiotic treatment 
for tuberculosis  
partial agonist of NMDA-type gluta-
mate receptors 
Wilhelm et al. 2008 [160] 
Kushner et al. 2007 [161] 
^Storch et al. 2007 [162] 
optimal DCS administra-
tion may improve treatment 
response when combined 
with behavioral therapy 
*OCD symptoms induced by drug treatments in patients that were not previously diagnosed with OCD, therefore these are not technically OCD studies per se. 
^This study found no evidence of improvements with DCS treatment, however it was suggested that these findings were due to sub-optimal timing of DCS administration. 
N/A, not applicable. 
ders. Taken together, the results of these open-label trials 
with riluzole have been remarkably consistent, with roughly 
half of the patients treated thus far experiencing significant 
treatment response. For a very recent comprehensive review 
on riluzole’s mechanism of action and use in psychiatric 
conditions see [135]. 
Anticonvulsant/Antiepileptic Drugs 
  Topiramate is classified as an anticonvulsant/antiepileptic 
drug (AED) that is approved by the FDA for treating epi-
lepsy. The structure of topiramate differs from other known 
AEDs, which may indicate a unique mechanism of action. 
Proposed mechanisms of action include block of voltage-
dependent Na
+ and K
+ channels, a positive modulatory effect 
on GABAA receptors, and a negative modulatory effect on 
AMPA/kainite-type glutamate receptor phosphorylation and 
ion channel conductance, and these actions may involve neu-
rons and astrocytes [136]. One or more of these mechanisms 
may account for the anti-glutamatergic properties of topi-
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augmentation in treatment resistant OCD, 11 of the 16 pa-
tients analyzed showed improvement in OCD symptoms 
[137]. An additional single case report for topiramate plus 
the SSRI paroxetine in treatment resistant OCD also supports 
the potential beneficial effects of this drug [138]. Lamo-
trigine is also an AED that has been approved by the FDA 
for the treatment of epilepsy and bipolar disorder. Evidence 
to merit the use of lamotrigine as an augmenting agent in 
OCD treatment is less convincing than for topiramate. In a 
case study of 8 OCD patients that previously failed to re-
spond to SSRIs alone, augmentation with lamotrigine only 
benefited one patient [139]. It should also be noted there 
have been case reports for both topiramate and lamotrigine 
potentially causing OCD-like symptoms [140-143].  
mGluR2 Targeting Agents 
  One of the more promising avenues to explore will be 
drugs that modulate metabotropic glutamate receptors 
(mGluRs). In particular, mGluR2 (which is strongly ex-
pressed in the forebrain) has extra- or peri-synaptic localiza-
tion on presynaptic membranes of excitatory axons and func-
tion as an autoreceptor [144]. Thus, activation of mGluR2 on 
excitatory neurons negatively modulates neurotransmitter 
release. Importantly, excessive neuronal activity leading to 
glutamate spillover seems to be required for activation of 
mGluR2, suggesting that its function may be to protect 
against pathological bouts of glutamatergic hyperexcitability 
[144]. Two agents aimed at modulating mGluR2 function by 
distinct routes have recently been proposed for the treatment 
of OCD.  
  N-acetylcysteine (NAC) is an amino acid derivative that 
stimulates the glial cystine/glutamate exchanger and leads to 
elevated extracellular glutamate levels. This rise in glutamate 
levels in the extrasynaptic space activates inhibitory mGluR2 
receptors that dampen synaptic release of glutamate from 
neurons [145]. This mechanism of action prompted a case 
study of NAC in combination with the SSRI fluvoxamine in 
treatment-refractory OCD that yielded evidence for signifi-
cant improvement in OCD symptoms [146]. Larger, well 
controlled studies are needed to further explore the potential 
of NAC in treating OCD symptoms. Since elevating ex-
tracellular/extrasynaptic glutamate by stimulating cystine 
exchange could also activate NMDA receptors similar to 
spillover effects of synaptically released glutamate [147], 
this aspect should not be overlooked in searching for the 
appropriate therapeutic dose of NAC. 
  LY354740 is an mGluR2/3 (type II) agonist. This drug 
showed potential in treating generalized anxiety disorders in 
humans, which might have relevance to OCD, but evidence 
to support this claim are restricted almost entirely to results 
from animal models of anxiety [148]. In contrast, the mGluR 
2/3 antagonists MGS0039 and LY341495 have been shown 
to inhibit marble burying in mice (considered by some to 
represent OCD-like behaviors) to a similar extent as SSRIs 
[149]. The agonist LY354740 attenuated this effect but did 
not affect marble burying behavior on its own. Clearly, fur-
ther preclinical work is needed to clarify the therapeutic po-
tential of mGluR2/3 agonists and antagonists in the context 
of OCD. Testing these drugs in a better established animal 
model for OCD-like behaviors will help to dissociate effects 
on compulsive behaviors versus generalized anxiety. 
NMDA-Type Glutamate Receptor Targeting Agents 
  Memantine is an NMDA receptor open channel blocker 
(antagonist) that has received FDA approval for the treat-
ment of Alzheimer’s disease (AD). Attractive features of 
memantine action include its low affinity and voltage-
dependence of NMDA receptor blockade, which may permit 
low level NMDA receptor activation during normal bouts of 
synaptic activity. Evidence from a small number of case 
studies supported a positive effect of memantine in some 
patients with treatment refractory OCD [150, 151]; however, 
other attempts to treat a limited number of OCD patients 
with memantine have proved unsuccessful [51].  
  Amantadine is structurally and functionally related to 
memantine and has recently been shown to inhibit marble 
burying in mice [152]. The overall effectiveness of aman-
tadine in this model was more favorable than memantine and 
riluzole. This result led the authors to propose the use of 
amantadine in the treatment of OCD. Amantadine has not 
been tested in OCD but has been approved by the FDA as an 
antiviral medication and is used in the treatment of Parkin-
son’s disease (PD). Curiously, an in vitro study comparing 
amantadine and memantine action in neurons from different 
brain regions suggested that at therapeutically relevant doses 
amantadine is more active in the striatum, whereas meman-
tine is more active in other brain structures [153]. The basis 
for this functional dichotomy is unknown, but nonetheless 
may hint at greater potential for amantadine over memantine 
in treating OCD. 
  Dizocilpine (also called MK-801) is another NMDA re-
ceptor open pore blocker. This drug seems to exacerbate 
rather than ameliorate OCD symptoms based on tests in the 
D1CT mice [154]. This result may reflect elevations in fore-
brain glutamate by dizocilpine similar to a mechanism de-
scribed for phencyclidine [155], but which seems paradoxi-
cal for a glutamate receptor antagonist. This effect is most 
likely mediated by block of NMDA receptors located on 
GABAergic interneurons that normally suppress forebrain 
glutamate release from excitatory neurons [154]. No such 
effect has been described for memantine or amantadine, al-
though the possibility should be explored. Dizocilpine action 
at NMDA receptors differs significantly from memantine 
and amantadine (e.g. trapping versus partial-trapping channel 
block [156]) making it a more potent NMDA receptor an-
tagonist that drastically interferes with brain function.  
  D-cycloserine (DCS) is a partial agonist of the NMDA 
receptor [157, 158]. Since NMDA receptor activation is 
critical for learning and memory, DCS is regarded as a cog-
nitive enhancer. DCS facilitates amygdala-dependent fear 
extinction (a process requiring NMDA receptor dependent 
long-term potentiation) [159], suggesting that it may be help-
ful in conjunction with extinction-based behavioral therapies 
for human OCD patients. Three trials examining DCS aug-
mentation of behavioral therapy in OCD have been com-
pleted. Two studies demonstrated more rapid or more pro-
nounced treatment response with DCS [160], at least for ini-
tial sessions [161], while the third study did not find evi-
dence of improvements with DCS [162]. The negative result 
of Storch et al. [162] may have resulted from high DCS 
doses or sub-optimal timing of DCS administration with re-
spect to the behavioral therapy [163].  72    Current Chemical Genomics, 2008, Volume 2  Ting and Feng 
 While not all glutamatergic neurotransmission-
modulating agents have proven beneficial in early trials for 
the treatment of OCD, the majority of these agents do seem 
to influence symptom severity (i.e. ameliorate or exacer-
bate), indicating a critical involvement of the glutamatergic 
neurotransmitter system in OCD. However, at this early 
stage the evidence surrounding even the most promising glu-
tamatergic neurotransmission-modulating agent riluzole con-
sists of just a few dozen OCD cases. No strong conclusions 
should be drawn about the usefulness of riluzole (or any 
other such drug) for the treatment of OCD prior to the com-
pletion of properly controlled, large-scale clinical trials. 
SUMMARY 
  In recent years, diverse lines of evidence have converged 
to implicate glutamatergic synaptic dysfunction within the 
CSTC brain circuit in the etiology of OCD. Genetic studies 
on the glutamatergic system, though relatively few thus far, 
have consistently supported this model and may ultimately 
establish the causal link(s) in OCD. These findings have led 
to new targets for the treatment of this often difficult to treat 
disorder, and the initial results with several agents that 
modulate the glutamatergic neurotransmitter system have 
been promising—suggesting perhaps that more efficient 
treatment options for OCD may soon be attainable. Most of 
the agents in testing are believed to have the net effect of 
reducing glutamate output or signaling, which may serve to 
normalize pathologically elevated glutamatergic transmis-
sion in the CSTC circuit in OCD. Alternatively, DCS acts as 
an enhancer of glutamatergic signaling through NMDA re-
ceptors, and is likely to exert its effects through actions on 
the fear extinction circuit of the amygdala that controls anxi-
ety. These interpretations are tentative at this early stage, but 
may provide useful insights for the development of novel 
glutamatergic neurotransmission-modulating agents. The 
implementation of animal models of OCD for preclinical 
drug screening can significantly speed progress in this area, 
and although the lack of demonstrated predictive validity has 
been a major criticism of OCD models in recent years, at 
least one genetic animal model has emerged that has both 
predictive validity and has provided clear evidence for the 
involvement of CSTC circuit dysfunction. Utilizing such 
tools to explore and define the synaptic basis of OCD should 
greatly advance our knowledge concerning a broad spectrum 
of poorly understood human disorders. 
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